SCHEMBL5038872

SCHEMBL5038872

O=C(NO)C1CC2(CC2)CN(C(=O)O)C1C(=O)N1CC=C(c2ccccc2)CC1

nearest known ligand 0.83

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ADAM10 O14672 20/20 0.83
MMP2 P08253 19/20 0.83
MMP9 P14780 13/20 0.83
MMP3 P08254 7/20 0.83
ERBB2 P04626 5/20 0.83
MMP12 P39900 1/20 0.83
MMP14 P50281 1/20 0.83
ADAM8 P78325 1/20 0.83
ADAM17 P78536 1/20 0.83
ADAM33 Q9BZ11 1/20 0.83
MMP1 P03956 3/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4337359 1.00 ADAM10 (0.83) ADAM10MMP2MMP9MMP3ERBB2
SCHEMBL15428480 1.00 ADAM10 (0.83) ADAM10MMP2MMP9MMP3ERBB2
SCHEMBL1366994 0.92 ADAM10 (0.83) ADAM10MMP2MMP9MMP3ERBB2
SCHEMBL1366294 0.92 ADAM10 (0.83) ADAM10MMP2MMP9MMP3ERBB2
SCHEMBL17288026 0.91 ADAM10 (0.82) ADAM10MMP2MMP9MMP3ERBB2
SCHEMBL4323548 0.91 ADAM10 (0.82) ADAM10MMP2MMP9MMP3ERBB2
SCHEMBL209111 0.91 ADAM10 (1.00) ADAM10MMP2MMP9MMP3ERBB2
SCHEMBL1366486 0.91 ADAM10 (1.00) ADAM10MMP2MMP9MMP3ERBB2
SCHEMBL4336513 0.90 ADAM10 (0.70) ADAM10MMP2MMP9MMP3ERBB2
SCHEMBL4342726 0.90 ADAM10 (0.68) ADAM10MMP2MMP9MMP3ERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1622569-B1 AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES INCYTE CORP (US) 2015-12-02 EP claimed
EP-1622569-A4 AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES INCYTE CORP (US) 2008-08-27 EP claimed
EP-1622569-A2 AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES Incyte Corporation (US) 2006-02-08 EP claimed
WO-2004096139-A2 AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES INCYTE CORPORATION (US) 2004-11-11 WO claimed
US-10226459-B2 Aza spiro alkane derivatives as inhibitors of metalloproteases INCYTE HOLDINGS CORPORATION (US) 2019-03-12 US disclosed
US-20180153882-A1 AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases INCYTE CORPORATION 2018-06-07 US disclosed
EP-2617419-A1 Aza spiro alkane derivatives as inhibitors of metallproteases Incyte Corporation (US) 2013-07-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10226459-B2 Aza spiro alkane derivatives as inhibitors of metalloproteases MMP9, MMP3, MMP12 ADAM10 29/4885MMP2 23/4885MMP9 1/4885
US-20180153882-A1 AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases MMP9, MMP3, MMP12 ADAM10 29/4885MMP2 23/4885MMP9 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.